International Journal of Science and Research Archive
eISSN: 2582-8185
Cross Ref DOI: 10.30574/ijsra
Journal homepage: https://ijsra.net/

(REVIEW ARTICLE)

Check for updates

DROPERIDOL VERSUS HALOPERIDOL FOR ACUTE AGITATION IN THE EMERGENCY DEPARTMENT: A REVIEW OF EFFICACY, SAFETY, AND CLINICAL OUTCOMES

Yash Sanghvi *

A.T. Still University of Health Sciences, School of Osteopathic Medicine in Arizona.
* Corresponding Author

ORCID Details
Yash Sanghvi: https://orcid.org/0009-0006-5043-2268

International Journal of Science and Research Archive, 2026, 20(03), 018–023

Publication history: Received on 17 July 2026; revised on 29 August 2026; accepted on 31 August 2026

Article DOI: https://doi.org/10.30574/ijsra.2026.20.3.1697

ABSTRACT

Acute agitation is a common and potentially dangerous presentation in the emergency department. When verbal de-escalation is unsuccessful or cannot be safely performed, medications may be required to rapidly control agitation and allow further medical evaluation. Haloperidol has historically been one of the most commonly used antipsychotic medications for this purpose. However, droperidol has gained renewed interest because of its rapid onset of action and effectiveness in controlling acute agitation. This review compares droperidol and haloperidol for the treatment of acute agitation in the emergency department, focusing on time to adequate sedation, need for repeat or rescue medications, adverse effects, QT prolongation, extrapyramidal symptoms, respiratory complications, and practical considerations for emergency physicians. Available evidence suggests that both medications are effective, but droperidol may provide faster and more reliable control of agitation and may decrease the need for additional medication. Concerns regarding QT prolongation remain important with both medications, although serious cardiac events associated with droperidol appear uncommon at doses typically used in emergency medicine. Current emergency medicine guidelines support droperidol as an effective option for severe agitation while continuing to recognize haloperidol as an appropriate treatment.

Keywords: Droperidol; Haloperidol; Acute Agitation; Emergency Medicine; Chemical Sedation; Rapid Tranquilization

1 INTRODUCTION

Acute agitation is frequently encountered in the emergency department and can result from psychiatric illness, intoxication, delirium, metabolic abnormalities, neurologic disease, or other medical conditions. Severely agitated patients may represent an immediate danger to themselves, healthcare workers, and other patients. At the same time, agitation can make it difficult for clinicians to perform the medical evaluation needed to identify the underlying cause.

Verbal de-escalation should generally be attempted when it can be performed safely. However, medications may become necessary when agitation is severe or when patient and staff safety is threatened [1].

Haloperidol has traditionally been one of the most commonly used antipsychotic medications for acute agitation. It is familiar to emergency physicians, inexpensive, and can be administered through several routes. However, haloperidol may have a relatively slow onset of action and can cause adverse effects such as extrapyramidal symptoms and QT prolongation [1].

Droperidol is another first-generation antipsychotic medication with a similar mechanism of action. Although droperidol use decreased substantially after concerns regarding QT prolongation and cardiac arrhythmias, interest in the medication has returned as additional evidence has supported its effectiveness and overall safety in emergency department patients [2].

The American College of Emergency Physicians currently recommends droperidol, particularly in combination with midazolam, as one of the preferred medication strategies for severe agitation. Haloperidol alone or combined with lorazepam also remains an accepted treatment [1].

This review compares droperidol and haloperidol for acute agitation in the emergency department, focusing on speed of sedation, need for additional medication, adverse effects, cardiac safety, and practical considerations.

1.1 Mechanism of Action

Droperidol and haloperidol are both first-generation antipsychotic medications belonging to the butyrophenone class. Their primary effect involves blocking dopamine D2 receptors within the central nervous system.

Reducing dopamine signaling can decrease psychomotor agitation and produce a calming effect. This makes both medications useful for patients with severe agitation, particularly when psychosis or intoxication contributes to the presentation.

Although their mechanisms are similar, their pharmacologic characteristics are not identical. Droperidol generally has a faster onset of action when administered parenterally, which can be particularly useful in the emergency setting.

The goal of treatment should not necessarily be to render the patient unconscious. Instead, medication should provide enough control of dangerous agitation to allow safe evaluation and treatment while minimizing excessive sedation and medication-related complications [1].

1.2 Time to Adequate Sedation

Speed is one of the most important considerations when choosing a medication for severe agitation. Every additional minute of uncontrolled agitation can increase the risk of injury to the patient and healthcare staff and can delay evaluation of potentially serious underlying medical conditions.

Evidence suggests that droperidol may provide faster control of agitation than haloperidol.

An early randomized, double-blind trial directly compared intramuscular droperidol with intramuscular haloperidol in acutely agitated patients [3]. Patients treated with droperidol were less likely to require another injection 30 minutes after the initial medication, suggesting more rapid and reliable control of agitation.

A larger randomized controlled trial later compared intramuscular droperidol and haloperidol for acute behavioral disturbance [4]. Both medications successfully produced sedation in the majority of patients. The results supported droperidol as an effective alternative to haloperidol for rapid control of agitation.

Current American College of Emergency Physicians guidance also reflects the importance of rapid sedation. For severe agitation, the guideline favors droperidol combined with midazolam or an atypical antipsychotic combined with midazolam when rapid and effective treatment is required [1].

When a single medication is necessary, droperidol is specifically identified as an appropriate option [1].

1.3 Need for Additional Medication

An ideal medication for agitation should not only work quickly but should also reduce the need for repeated injections or additional sedating medications.

Repeated medication administration increases nursing workload, delays evaluation, and may increase the risk of excessive sedation or respiratory complications.

Direct comparison studies suggest that droperidol may decrease the need for additional medication compared with haloperidol [3,5].

A recent multicenter retrospective emergency department study compared patients receiving intramuscular droperidol with those receiving intramuscular haloperidol for acute agitation [5]. Patients initially treated with droperidol required fewer additional doses of antipsychotics or benzodiazepines during the following four hours.

The droperidol group required an average of approximately 0.75 additional doses compared with 1.1 additional doses among patients initially receiving haloperidol [5].

Although the absolute difference was relatively small, reducing repeated medication administration may be clinically meaningful in a busy emergency department.

1.4 Effectiveness

Both medications are effective for controlling acute agitation.

A Cochrane review examining droperidol for aggression and agitation found that droperidol was effective for rapid tranquilization. When compared directly with haloperidol, the available evidence generally supported similar overall effectiveness, although the limited number and size of studies made it difficult to establish a large difference between the medications [6].

A broader systematic review and network meta-analysis of medications used for severe agitation in emergency departments similarly demonstrated that several medications and medication combinations can successfully achieve rapid tranquilization [2].

The evidence therefore does not suggest that haloperidol is ineffective. Rather, droperidol may provide advantages related to the speed and reliability of sedation.

1.5 QT Prolongation and Cardiac Safety

One of the most important concerns surrounding droperidol involves QT prolongation.

In 2001, the United States Food and Drug Administration issued a boxed warning for droperidol because of reports of QT prolongation and torsades de pointes. This warning led to a major decrease in droperidol use.

However, subsequent research has questioned whether the risk of serious arrhythmia was overestimated, particularly when droperidol is used at typical emergency department doses [2].

Both droperidol and haloperidol can prolong the QT interval. Therefore, neither medication is completely free of cardiac risk.

Patients with known long-QT syndrome, significant electrolyte abnormalities, bradycardia, structural heart disease, or concurrent use of other QT-prolonging medications may require additional caution.

For a severely agitated patient who represents an immediate danger, obtaining an electrocardiogram before medication administration may not always be practical. Emergency physicians must therefore balance the immediate risks associated with uncontrolled agitation against the potential medication-related cardiac risk.

Current emergency medicine guidelines continue to support the use of droperidol despite its historical boxed warning [1].

2 EXTRAPYRAMIDAL SYMPTOMS

Both medications can produce extrapyramidal symptoms because of dopamine blockade.

Possible complications include acute dystonia, akathisia, and other abnormal muscle movements. Haloperidol has traditionally been associated with concern for extrapyramidal reactions, particularly at higher doses.

A recent direct comparison of droperidol and haloperidol in emergency department patients found no significant difference in documented extrapyramidal symptoms between the groups [5].

Clinicians should nevertheless monitor patients receiving either medication for these complications.

2.1 Respiratory Complications and Excessive Sedation

Another important concern with medications used for agitation is excessive sedation.

Antipsychotics alone generally cause less respiratory depression than medications such as benzodiazepines. However, the risk can increase when multiple sedating medications are combined.

This is particularly relevant because droperidol and haloperidol are frequently administered with benzodiazepines when agitation is severe.

Current evidence has not demonstrated a clear difference in serious respiratory complications between droperidol and haloperidol when appropriately used [2,4].

Regardless of which medication is selected, severely agitated patients receiving parenteral sedation should undergo appropriate reassessment and physiologic monitoring.

2.2 Advantages of Droperidol

Droperidol has several potential advantages in the emergency department.

The most important is its relatively rapid onset of action. Faster control of dangerous agitation can improve safety for the patient and emergency department staff while allowing the medical evaluation to begin sooner.

Droperidol may also reduce the need for repeat medication administration [3,5].

These advantages are reflected in current American College of Emergency Physicians recommendations. When a single agent is required for severe agitation, droperidol is one of the preferred medications. The combination of droperidol and midazolam receives an even stronger role when rapid and effective sedation is required [1].

The major disadvantage of droperidol remains concern regarding QT prolongation and its associated boxed warning, although the actual rate of serious cardiac complications appears to be low when the medication is appropriately used [2].

2.3 Advantages of Haloperidol

Haloperidol remains an important medication for emergency department agitation.

One of its greatest advantages is familiarity. Emergency physicians, nurses, and pharmacists have decades of experience using haloperidol for agitation. It is widely available and inexpensive.

Haloperidol can also be combined with benzodiazepines such as lorazepam when additional sedation is required. Current American College of Emergency Physicians guidelines continue to recognize haloperidol alone or in combination with lorazepam as an effective option for severe agitation [1].

However, compared with droperidol, haloperidol may take longer to achieve adequate sedation and may require additional medication [3,5].

3 PRACTICAL CONSIDERATIONS IN THE EMERGENCY DEPARTMENT

Medication selection for agitation cannot be based solely on which drug produces sedation fastest.

The underlying cause of agitation should be considered whenever possible. A patient experiencing psychosis may require a different approach than a patient with alcohol intoxication, stimulant toxicity, delirium, hypoxia, hypoglycemia, or another medical emergency.

The severity of agitation also matters. A cooperative patient with mild agitation may be managed with verbal de-escalation or oral medication. A patient who is actively violent and placing themselves or staff at immediate risk may require rapid intramuscular medication.

Emergency physicians must also consider medication availability, previous response to treatment, allergies, cardiac history, other medications, substance use, and the ability to appropriately monitor the patient after medication administration.

The ideal medication therefore depends on both the clinical situation and the patient.

4 DISCUSSION

Droperidol and haloperidol are both effective medications for acute agitation, but available evidence suggests several potential advantages of droperidol in the emergency department.

The primary advantage appears to be speed and reliability. Direct comparisons have demonstrated that droperidol can provide rapid sedation and may decrease the need for additional medications [3-5].

A recent multicenter emergency department study provides additional support for this difference. Patients receiving droperidol required significantly fewer additional antipsychotic or benzodiazepine doses during the following four hours than patients receiving haloperidol [5].

Current American College of Emergency Physicians guidance is consistent with these findings. The guideline provides a Level B recommendation for droperidol combined with midazolam for more rapid and effective management of severe agitation. When monotherapy is necessary, droperidol is also recommended as an appropriate single agent. Haloperidol alone or combined with lorazepam remains an effective alternative [1].

Safety requires more careful interpretation. Droperidol has historically been associated with concern for QT prolongation because of its boxed warning. However, later studies and reviews have suggested that serious cardiac complications are uncommon when droperidol is appropriately used [2].

Haloperidol also carries risks, including QT prolongation and extrapyramidal symptoms. Therefore, choosing haloperidol simply to avoid the cardiac concerns associated with droperidol does not eliminate medication-related risk.

From an emergency medicine perspective, droperidol may offer an important advantage when rapid control is necessary. Faster sedation can reduce the amount of time that a severely agitated patient remains a danger to themselves or others and may allow earlier medical evaluation.

However, medication should remain only one part of managing agitation. Clinicians must continue to evaluate for underlying medical causes, use verbal de-escalation whenever appropriate, monitor patients following medication administration, and individualize medication selection.

Limitations

The evidence directly comparing droperidol and haloperidol has several limitations.

- Some randomized trials were conducted outside traditional emergency departments, including psychiatric intensive care settings [4]. Study populations also differ in the causes and severity of agitation.
- Medication doses, routes of administration, definitions of adequate sedation, and use of additional benzodiazepines vary considerably between studies.
- Several studies are also relatively old, while newer evidence includes retrospective observational studies that are vulnerable to selection bias and differences in local medication protocols.

These limitations make it difficult to determine the exact degree to which droperidol is superior to haloperidol.

Further large randomized trials directly comparing standardized droperidol and haloperidol protocols in emergency department patients would help clarify differences in time to sedation, rescue medication requirements, adverse events, and patient-centered outcomes.

5 CONCLUSION

Droperidol and haloperidol are both effective medications for treating acute agitation in the emergency department. Haloperidol remains widely used because of its familiarity, availability, and long history in emergency and psychiatric care.

However, available evidence suggests that droperidol may provide faster and more reliable sedation and may decrease the need for additional medications. These characteristics are particularly important in the emergency department, where prolonged severe agitation can place both patients and healthcare workers at risk.

Concerns regarding QT prolongation should be considered when using either medication. Although droperidol carries a boxed warning related to QT prolongation and torsades de pointes, serious cardiac events appear uncommon with typical emergency department use.

Current American College of Emergency Physicians recommendations support droperidol as an effective option for severe agitation and favor droperidol combined with midazolam when particularly rapid and effective sedation is necessary. Haloperidol alone or combined with lorazepam remains an appropriate alternative.

Based on current evidence, droperidol may offer practical advantages over haloperidol for acute agitation, particularly when rapid control is necessary. However, medication selection should ultimately be based on the cause and severity of agitation, patient-specific risks, clinician experience, and available monitoring.

STATEMENTS ON COMPLIANCE WITH ETHICAL STANDARDS

Disclosure of conflict of interest

The author declares no conflicts of interest regarding this manuscript

REFERENCES

[1] American College of Emergency Physicians Clinical Policies Subcommittee (WritingCommittee) on Severe Agitation, Thiessen MEW, Godwin SA, Hatten BW, Whittle JA, Haukoos JS, Diercks DB. Clinical policy: Critical issues in the evaluation and management of adult out-of-hospital or emergency department patients presenting with severe agitation. Ann Emerg Med. 2024;83(1):e1-e30. doi:10.1016/j.annemergmed.2023.09.010

[2] Cole JB, Lee SC, Martel ML, Smith SW, Biros MH, Miner JR. The incidence of QTprolongation and torsades des pointes in patients receiving droperidol in an urban emergency department. West J Emerg Med. 2020;21(4):728-736. doi:10.5811/westjem.2020.4.47036.

[3] Alshehri AM, Crowley KE, Lupi KE, Kim CS, DeGrado JR, Marino K. Evaluation ofdroperidol use in the emergency department: a retrospective analysis of QTc prolongation and adverse events. BMC Emerg Med. 2024;24(1):232. doi:10.1186/s12873-024-01158-9.

[4] Resnick M, Burton BT. Droperidol vs. haloperidol in the initial management of acutelyagitated patients. J Clin Psychiatry. 1984;45(7):298-299.

[5] Knott JC, Taylor DM, Castle DJ. Randomized clinical trial comparing intravenousmidazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Ann Emerg Med. 2006;47(1):61-67. doi:10.1016/j.annemergmed.2005.07.003.

[6] DiGuglielmo F, D'Amico M, Martine J, Sastic C, Vuong T. Comparison of droperidol andhaloperidol for acute agitation in the emergency department: a retrospective cohort study. Ment Health Clin. 2025;15(5):232-236. doi:10.9740/mhc.2025.10.232.

[7] Calver L, Isbister GK. High dose droperidol and QT prolongation: analysis of continuous12-lead recordings. Br J Clin Pharmacol. 2014;77(5):880-886. doi:10.1111/bcp.12272.

[8] Martel ML, Driver BE, Miner JR, Biros MH, Cole JB. Randomized double-blind trial ofintramuscular droperidol, ziprasidone, and lorazepam for acute undifferentiated agitation in the emergency department. Acad Emerg Med. 2021;28(4):421-434. doi:10.1111/acem.14124.

[9] Calver L, Page CB, Downes MA, Chan B, Kinnear F, Wheatley L, et al. The safety andeffectiveness of droperidol for sedation of acute behavioral disturbance in the emergency department. Ann Emerg Med. 2015;66(3):230-238.e1. doi:10.1016/j.annemergmed.2015.03.016.

[10] deSouza IS, Thode HC Jr, Shrestha P, Allen R, Koos J, Singer AJ. Rapid tranquilizationof the agitated patient in the emergency department: a systematic review and network meta-analysis. Am J Emerg Med. 2022;51:363-373. doi:10.1016/j.ajem.2021.11.011.